The FDA approved nemolizumab (Nemluvio) in combination with prescription topical agents for the treatment of moderate-to-severe atopic dermatitis, drugmaker Galderma announced. A monoclonal ...

The ruxolitinib cream met its primary end point as a treatment for prurigo nodularis in one phase 3 trial but fell short in ...

The FDA has approved these four biologics to treat atopic dermatitis: dupilumab, lebrikizumab, nemolizumab, and tralokinumab. They are all types of biologics called monoclonal antibodies.

The European Commission has approved nemolizumab (Nemluvio) for subcutaneous use in treating moderate to severe atopic dermatitis (AD) in patients aged ≥ 12 years and moderate to severe prurigo ...

Dermatology specialist Galderma has claimed a second FDA approval for IL-31 inhibitor Nemluvio, adding atopic dermatitis to its label. Nemluvio (nemolizumab) – which was approved by the FDA in ...

Nemolizumab is approved for use alongside topical therapies ... new active substance work-sharing initiative procedure. The drug has also been approved in the European Union, the United States ...

Nemluvio is also approved by the U.S. Food and Drug Administration for the treatment ... trials evaluated the efficacy and safety of nemolizumab administered subcutaneously every four weeks ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine nemolizumab (brand name Nemluvio) for the treatment of two skins conditions – moderate to severe prurigo ...

Ad hoc announcement pursuant to Art. 53 LR This approval from the European Commission is based on robust results from the phase III OLYMPIA and ARCADIA clinical trial programs, showing that ...

“Nemolizumab's benefits have been demonstrated ... Nemluvio is also approved by the U.S. Food and Drug Administration for the treatment of atopic dermatitis and prurigo nodularis.

“Nemolizumab’s benefits have been ... Nemluvio is also approved by the U.S. Food and Drug Administration for the treatment of atopic dermatitis and prurigo nodularis. 12 It is under review ...